117 related articles for article (PubMed ID: 25879335)
21. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer.
Zhu WY; Hunag YY; Liu XG; He JY; Chen DD; Zeng F; Zhou JH; Zhang YK
Anat Rec (Hoboken); 2012 Feb; 295(2):208-14. PubMed ID: 22190510
[TBL] [Abstract][Full Text] [Related]
22. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
[TBL] [Abstract][Full Text] [Related]
23. Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.
Ge J; Chen Z; Wu S; Chen J; Li X; Li J; Yin J; Chen Z
Digestion; 2009; 80(3):148-58. PubMed ID: 19713703
[TBL] [Abstract][Full Text] [Related]
24. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction.
Li S; Li B; Wang J; Zhang D; Liu Z; Zhang Z; Zhang W; Wang Y; Bai D; Guan J; Zhang Y
Oncol Res; 2017 Jan; 25(1):93-97. PubMed ID: 28081737
[TBL] [Abstract][Full Text] [Related]
25. Chemoresponse after non-curative gastrectomy for M1 gastric cancer.
Shin HB; Lee SH; Son YG; Ryu SW; Sohn SS
World J Surg Oncol; 2015 Jan; 13():13. PubMed ID: 25634223
[TBL] [Abstract][Full Text] [Related]
26. [Expression and significance of P-glycoprotein, glutathione S-transferase-pi and Topoisomerase II in gastric carcinomas].
Qin F; Qin X; Zhang X; Jia HW
Ai Zheng; 2002 Feb; 21(2):167-70. PubMed ID: 12479068
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
28. The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
Geng M; Wang L; Chen X; Cao R; Li P
Diagn Pathol; 2013 Dec; 8():198. PubMed ID: 24326092
[TBL] [Abstract][Full Text] [Related]
29. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Bai M; Goussia A; Samantas E; Galani E; Tsavdaridis D; Karina M; Papakostas P; Konstantara A; Fountzilas G
Anticancer Res; 2007; 27(4C):2973-83. PubMed ID: 17695481
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer.
Shi C; Yang B; Chen Q; Yang J; Fan N
Oncology; 2011; 80(5-6):289-95. PubMed ID: 21778768
[TBL] [Abstract][Full Text] [Related]
32. Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.
Kim WJ; Kakehi Y; Wu WJ; Fukumoto M; Yoshida O
Br J Urol; 1996 Sep; 78(3):361-8. PubMed ID: 8881943
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
34. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
Zhang Q; Tey J; Peng L; Yang Z; Xiong F; Jiang R; Liu T; Fu S; Lu JJ
Radiother Oncol; 2012 Jan; 102(1):51-5. PubMed ID: 22178689
[TBL] [Abstract][Full Text] [Related]
36. [Long-term outcome and analysis of prognostic factors in 114 cases of postoperative stage III gastric cancer].
Zhang Y; Ma LW
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):863-6. PubMed ID: 24447487
[TBL] [Abstract][Full Text] [Related]
37. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
38. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
[TBL] [Abstract][Full Text] [Related]
39. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
[TBL] [Abstract][Full Text] [Related]
40. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
